Compare CLPT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPT | AKBA |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.5M | 375.0M |
| IPO Year | 2009 | 2014 |
| Metric | CLPT | AKBA |
|---|---|---|
| Price | $11.57 | $1.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $4.67 |
| AVG Volume (30 Days) | 496.1K | ★ 5.0M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,971,000.00 | N/A |
| Revenue This Year | $45.67 | N/A |
| Revenue Next Year | $19.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.78 | N/A |
| 52 Week Low | $8.27 | $0.88 |
| 52 Week High | $30.10 | $4.08 |
| Indicator | CLPT | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 51.09 | 34.96 |
| Support Level | $10.09 | N/A |
| Resistance Level | $11.73 | $1.56 |
| Average True Range (ATR) | 0.96 | 0.08 |
| MACD | -0.11 | -0.03 |
| Stochastic Oscillator | 28.17 | 19.55 |
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.